Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22

scientific article published on 22 November 2011

Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22 is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1373/CLINCHEM.2011.174359
P698PubMed publication ID22110019

P50authorSabina A MurphyQ114308442
P2093author name stringChristopher P Cannon
David A Morrow
Eugene Braunwald
Petr Jarolim
E Wilson Grandin
Lea Ritterova
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectacute coronary syndromeQ266018
P304page(s)267-273
P577publication date2011-11-22
P1433published inClinical ChemistryQ849687
P1476titleGalectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22
P478volume58

Reverse relations

cites work (P2860)
Q34997796Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure
Q64233589Biomarkers in Routine Heart Failure Clinical Care
Q26991726Cardiac biomarkers: new tools for heart failure management
Q36877555Circulating Galectin-3 Is Associated With Cardiometabolic Disease in the Community
Q38687046Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure
Q34102031Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure
Q36917873Galectin 3 complements BNP in risk stratification in acute heart failure.
Q35931701Galectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation
Q90152813Galectin-3 Is a Potential Mediator for Atherosclerosis
Q49400435Galectin-3 and the incidence of abdominal aortic aneurysm: the atherosclerosis risk in communities (ARIC) study
Q33577541Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study
Q90690500Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure
Q36439679Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community
Q48159180Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.
Q90677157Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes
Q93099741Mechanisms of cardiac collagen deposition in experimental models and human disease
Q39017333Myocardial and Serum Galectin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling
Q38471023Prognostic value of galectin-3 in patients with heart failure
Q37580709Serial galectin-3 and future cardiovascular disease in the general population
Q38154222The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers
Q38761942The emerging role of galectins in cardiovascular disease
Q92474328The relationship between galectin-3 levels and fragmented QRS (fQRS) in patients with heart failure with reduced left ventricular ejection fraction

Search more.